Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712004 | 0.91 | SMN1; SMN2 (0.51) | KDM4ESMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL543758 | 0.85 | PSEN1 (0.51) | ROCK2HPGDHSD17B10ALDH1A1ROCK1 | |
| SCHEMBL544000 | 0.84 | ALOX5 (0.48) | ROCK2SMN1; SMN2WNT3AKDRFLT1 | |
| SCHEMBL543600 | 0.83 | KDR (0.55) | ROCK2KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL13380736 | 0.83 | KIT (0.43) | MEN1KMT2AMAPTALDH1A1TP53 | |
| SCHEMBL544093 | 0.83 | MEN1 (0.50) | KDM4ESMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL5712006 | 0.83 | ROCK2 (0.48) | ROCK2MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL543730 | 0.82 | KDR (0.48) | ROCK2ALDH1A1KDRFLT1FLT4 | |
| SCHEMBL543692 | 0.81 | ROCK2 (0.46) | ROCK2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL543650 | 0.81 | ALDH1A1 (0.42) | ALDH1A1CYP2C19KDRFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | claimed |
| EP-1684750-B1 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2010-04-28 | — | — | EP | claimed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | claimed |
| EP-1684750-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-08-02 | — | — | EP | claimed |
| WO-2005040139-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-05-06 | — | — | WO | claimed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2010-05-06 | — | — | US | disclosed |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | AB SCIENCE (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | MOUSSY ALAIN | 2007-10-25 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| EP-1684750-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005040139-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | ROCK2 317/4885KDM4E 432/4885SMN1; SMN2 4076/4885 |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | FGFR3, ABL1, FLT3 | ROCK2 739/4885KDM4E 529/4885SMN1; SMN2 4287/4885 |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | KIT, JAK3, MAP3K3 | ROCK2 90/4885KDM4E 858/4885SMN1; SMN2 4126/4885 |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | KIT, CPA3, CMA1 | ROCK2 1039/4885KDM4E 1106/4885SMN1; SMN2 4701/4885 |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | FGFR3, FLT3, ABL1 | ROCK2 544/4885KDM4E 493/4885SMN1; SMN2 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.